Iomai

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was incorporated in 1997 and is based in Gaithersburg, Maryland. Intercell USA, Inc. was formerly known as Iomai Corporation. As a result of the acquisition of Iomai Corporation by Intercell Ag, Iomai Corporation's name was changed. As of August 5, 2008, Intercell USA, Inc. operates as a subsidiary of Intercell Biomedical Research & Development AG.